Patient characteristics, type of cancer, ICI treatment, onset of vasculitis, ANCA type and treatment
| ID | Age (year) | Sex | Race | Type of cancer | ICI | Existing AAV before ICI | ANCA type | Timing of AAV after initiation of ICI (months) | Presenting findings | Treatment | Nadir sCr (mg/dL) | AAV status at last follow-up |
| 1 | 65 | M | C | Squamous cell carcinoma of left palatine tonsil | Pembrolizumab | N | MPO | 5 | AKI (sCr: 7.20 mg/dL) haematuria, proteinuria and foot drop | RTX+GC | 1.5 | Remission |
| 2 | 67 | F | C | Squamous cell cancer of the lung | Pembrolizumab | Y | PR3 | 1 | AKI (sCr: 2.5 mg/dL), haematuria and proteinuria | RTX+GC | 1.8 (baseline sCr) | Remission |
AAV, ANCA associated vasculitis; AKI, acute kidney injury; ANCA, anti-neutrophil cytoplasmic antibody; C, Caucasian; GC, glucocorticosteroids; ICI, Immune checkpoint inhibitor; MPO, myeloperoxidase; N, no; PR3, proteinase-3; RTX, rituximab; sCr, serum creatinine; Y, yes.